Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 34.85
- Piotroski Score 2.00
- Grade Neutral
- Symbol (AMAM)
- Company Ambrx Biopharma Inc.
- Price $28.00
- Changes Percentage (0.07%)
- Change $0.02
- Day Low $27.98
- Day High $28.00
- Year High $28.15
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 04/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.42
- Trailing P/E Ratio 66.666666666667
- Forward P/E Ratio 66.666666666667
- P/E Growth 66.666666666667
- Net Income $-77,996,000
Income Statement
Quarterly
Annual
Latest News of AMAM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Jack Flaherty, Yoshinobu Yamamoto Shine In World Series After Pursuits By The Yankees
The Yankees' frustrating losses in the World Series have led to contemplation of what-ifs, such as missed opportunities with pitchers Flaherty and Yamamoto. Despite close calls, the team remains hopef...
By Forbes | 3 weeks ago -
Yoshinobu Yamamoto delivers with World Series gem in Dodgers' Game 2 win over Yankees
Yoshinobu Yamamoto impressed with his pitching in Game 2, leading the Dodgers to victory. Despite a strong performance, he was taken out after facing Giancarlo Stanton....
By USA Today | 3 weeks ago -
Dodgers' Yoshinobu Yamamoto stymies Yankees in World Series Game 2 win as Shohei Ohtani injury casts shadow
Los Angeles Dodgers' Freddie Freeman hit a walk-off home run against the New York Yankees, securing a 4-2 victory. Dodgers' pitcher Yamamoto impressed, and despite some tense moments, Dodgers took a 2...
By Fox News | 3 weeks ago
